AIM

Molecular surveillance for polymorphisms associated with artemisinin-based combination therapy resistance in Plasmodium falciparum isolates collected in Mozambique, 2018

Background: Due to the threat of emerging anti-malarial resistance, the World Health Organization recommends incorporating surveillance for molecular markers of anti-malarial resistance into routine therapeutic efficacy studies (TESs). In 2018, a TES of artemether-lumefantrine (AL) and artesunate-amodiaq...

Rapid increase of Plasmodium falciparum dhfr/dhps resistant haplotypes, after the adoption of sulphadoxine-pyrimethamine as first line treatment in 2002, in southern Mozambique

Enosse, Sonia; Magnussen, Pascal; Abacassamo, Fatima; Gómez-Olivé, Xavier; M Rønn, Anita; Thompson, Ricardo; Alifrangis, Michael.

Malar. j. (Online); 7 (115), 2008

In late 2002, the health authorities of Mozambique implemented sulphadoxine-pyrimethamine (SP)/amodiaquine (AQ) as first-line treatment against uncomplicated falciparum malaria. In 2004, this has been altered to SP/artesunate in line with WHO recommendations of using Artemisinin Combination Therapies (AC...

Pyrimethamine/pharmacology, Protozoan Proteins/genetics, Malaria, Falciparum/epidemiology, d0161330, d0138120, Mozambique/epidemiology, Ligases, Drug Combinations, Drug Resistance/genetics, Ezetimibe, Simvastatin Drug Combination/therapeutic use, Pyrimethamine/supply & distribution, Pharmaceutical Preparations, Haplotypes/genetics, Malaria, Falciparum/therapy, Malaria, Falciparum/parasitology, Plasmodium falciparum/radiation effects, Plasmodium falciparum/isolation & purification, Protozoan Proteins/standards, Sulfadoxine/pharmacology

Fulltext